Breakthrough Presentations at AACR Annual Meeting
iTeos Therapeutics, Inc. (NASDAQ: ITOS), known for its cutting-edge research in immuno-oncology, has exciting news as it prepares for the American Association for Cancer Research (AACR) Annual Meeting. Set to take place soon, this annual gathering draws attention from leading minds in cancer research, and iTeos will be presenting groundbreaking preclinical data that may redefine treatment paradigms.
Showcasing EOS-215
One of the stars of the show will be EOS-215, an innovative antibody designed to target TREM2, a receptor believed to play a role in tumor growth regulation. This first-in-class therapeutic candidate aims to counteract tumor environments that generally prevent effective immune responses. Notably, EOS-215 has demonstrated impressive results in both in vitro and in vivo studies that reflect its promise in overcoming challenges related to immune resistance.
Understanding the PTPN1/2 Inhibitor
Alongside EOS-215, the team will present data on a novel small molecule that inhibits PTPN1 and PTPN2. These phosphatases act as negative regulators in crucial immune signaling pathways, and their inhibition can significantly enhance the efficacy of immune responses against tumors. iTeos’ innovative therapeutic approach has shown high oral bioavailability and potential to imbue cancer therapies with increased potency.
Event Details
The presentations will encompass two key abstracts that highlight not only the innovative pathways being explored but also the meticulous research backing these developments. The details for the presentations are as follows:
Abstract Presentation on EOS-215
Abstract 3136, titled "EOS-215, a first-in-class TREM2 antagonist, designed to reprogram the tumor microenvironment and overcome resistance," will be featured in the session focusing on experimental and molecular therapeutics.
- Session: Experimental and Molecular Therapeutics - Therapeutic Approaches to Attack the Tumor Microenvironment
- Date and Time: April 28, 2025, from 2:30 PM to 5:00 PM CDT
- Location: Poster Section 24
Abstract Presentation on PTPN Inhibitor
Abstract 5609 will address "A novel PTPN1/2 inhibitor with high oral bioavailability enhances the antitumoral response." This will also take place in a session dedicated to advanced kinase and phosphatase inhibitors.
- Session: Experimental and Molecular Therapeutics - Kinase and Phosphatase Inhibitors 3
- Date and Time: April 29, 2025, from 2:30 PM to 5:00 PM CDT
- Location: Poster Section 20
iTeos will also maintain a presence at their booth #3240 during the event, creating additional opportunities for engagement with attendees interested in their revolutionary approaches to cancer treatment.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is deeply committed to pioneering breakthroughs in cancer therapy through the development of innovative immuno-oncology therapeutics. The company utilizes its profound understanding of tumor immunology to create therapies that can potentially restore the immune response essential for combating cancer effectively. Their robust pipeline includes several clinical-stage programs that specifically target immunosuppressive mechanisms while being developed with enhanced pharmacologic properties to ensure better clinical outcomes.
Innovational Insights on EOS-215
EOS-215 represents a significant advancement within iTeos’ pipeline. This monoclonal antibody is uniquely positioned to block the binding of TREM2 ligands, effectively turning off tumor-promoting activities within the tumor-associated macrophages. This reprogramming is crucial for activating T cells, which are essential components of the immune system that fight cancer.
Advancing Research with PTPN Inhibition
The PTPN1/2 inhibitor by iTeos shows promise in reshaping the tumor microenvironment, which could improve responses to existing cancer therapies. By diminishing the suppressive signals from these phosphatases, a coordinated antitumor immune response can be triggered, empowering both cancer and immune cells to react more favorably to treatment.
Frequently Asked Questions
What is EOS-215?
EOS-215 is a monoclonal antibody developed by iTeos Therapeutics that targets TREM2, aiming to reprogram the immune response in cancer patients.
How does the PTPN1/2 inhibitor function?
This small molecule inhibits proteins that negatively regulate immune signaling, enhancing the ability of immune cells to respond to tumors.
When will iTeos present their findings?
iTeos will present their research at the AACR Annual Meeting, with sessions scheduled for April 28 and 29.
Where is iTeos Therapeutics based?
iTeos is headquartered in Watertown, Massachusetts, with a research facility located in Gosselies, Belgium.
How can I contact iTeos Therapeutics for more information?
For inquiries, interested parties can reach out via the investor contact, Carl Mauch, at carl.mauch@iteostherapeutics.com, or the media contact at media@iteostherapeutics.com.
